1.	BIBW 2992 and BSC Versus Placebo and BSC in Non-Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.23, NCT00656136
2.	An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-Negative Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.10, Eudract 2006-002018-36, NCT00425854
3.	BIBW 2992 in Head&Neck Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.28, 67,969 IND, NCT00514943
4.	LUX Lung 2 Phase II Single Arm BIBW 2992 in NSCLC With EGFR Activating Mutations Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.22, NCT00525148
5.	BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.5, EUDRACT2006-002814-37, NCT00708214
6.	Phase I/II Open Label Trial of Continuous Once Daily Oral Treatment With BIBW 2992 - Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib. Phase: Phase II Type: Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.33, NCT00711594
7.	BIBW 2992 With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.36, NCT00727506
8.	Phase II Trial of BIBW 2992 in Genetically Pre-Screened Cancers With EGFR and/or HER2 Gene Amplification. Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.26, NCT00748709
9.	BIBW2992 (TOVOK®) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.40, EUDRACT 2008-001264-37, NCT00796549
10.	6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 or Lapatinib or Trastuzumab Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.44, NCT00826267
11.	BIBW 2992 QTcF Trial in Patients With Relapsed or Refractory Solid Tumours Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.24, NCT00875433
12.	Study to Determine the Maximum Tolerated Dose of BIBW 2992 When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.37, EUDRACT2008 002613 43, NCT00716417
13.	Trial Exploring BIBW 2992 + Paclitaxel (Part A) and BIBW 2992 + Paclitaxel + Bevacizumab (Part B) in Patients With Advanced Solid Tumours Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.12, NCT00809133